Investor Relations:
Corporate Governance

Dr. Langer has served as a director of Quoin Inc. since 2019 and as a director of Quoin Ltd. since October 28, 2021. After graduating from Georgetown School of Medicine and Harvard Law School, Dr. Langer spent over 35 years in the pharmaceutical industry at Eli Lilly, Abbott, Searle, GSK and as President at Dr. Reddy’s Pharmaceuticals. He has also served as Chief Executive Officer at Neose Technologies, Inc. Dr. Langer has served as director at a number of companies including Sirna Therapeutics (acquired by Merck), Ception Therapeutics (acquired by Cephalon), Transkaryotic Therapies (acquired by Shire), Pharmacopeia (acquired by Ligand), Cytogen (acquired by EUSA Pharma), Brooklyn ImmunoTherapeutics, Inc. and Delcath Systems. Dr. Langer is currently a Director at Myriad Genetics, Dicerna Pharmaceuticals and Pernix Therapeutics. He is a Clinical Psychiatry Professor at Georgetown and serves on the Dean’s Advisory Board of Harvard Law School. He received an M.D. from Georgetown University School of Medicine, a J.D. from Harvard Law School, and a B.A. in Biology from Columbia University.

Ms. Leong has worked across four continents in valuation and transactions in sale, IPO, float, financial modeling, internal controls and raising capital. She has experience analyzing business plans, performing market analyses, preparing financial projections, developing valuation models, advising on equity transactions, mergers, acquisitions and corporate restructurings. Currently, Ms. Leong is Senior Vice President of Product Management for B.S.D Capital, Inc (d/b/a Lendistry). Previously, she held the positions of Head of Finance and Product Strategy and Head of Product Management for LoanStreet Inc. She was US lead for the Asset Liability Committee at RBC Capital Markets. At National Australia Bank, Ms. Leong was promoted to VP of Capital Insights. She has an MBA from Wharton School of Business, University of Pennsylvania, a BCom and a BA from the University of Melbourne.

Mr. Culverwell has served as a director of Quoin Inc. since April 2021 and as a director of Quoin Ltd. since October 28, 2021. He is also currently serving as the Chief Executive Officer and Chairman of the Board of Directors of HOX Therapeutics. He serves as a director and Audit Committee Chairman of TC BioPharm (Holdings) plc (Nasdaq: TCBP) and he serves as a director, Audit Committee Chairman, and member of the Compensation Committee of SafeGuard Biosystems. In 2005, Mr. Culverwell founded Sudbrook Associates, which provided strategic advice and fundraising services for life science companies. Previously, Mr. Culverwell was Senior Vice President and Global Coordinator Healthcare Research at Merrill Lynch. He also served as Director of Healthcare Equity Research at ABN Amro Bank N.V., director and Audit Committee Chairman of Amryt Pharma PLC (Nasdaq: AMYT), and director and Audit Committee Chairman of Innocoll AG. He received an MSc with honors from the University of Aberdeen.

Mr. Cooper has served as a director of Quoin Inc. since May 2021. With 30 years of pharmaceutical industry experience, Mr. Cooper has held roles in operational, corporate development and general management. He recently served as the Chief of Strategy and Corporate Development for Resonea, Inc., a digital health company. Formerly, he was President at Boulder Cove and Executive VP of Corporate and Product Development at Medicis Pharmaceutical. He also served as the Chief Business Officer of NuvOx Pharmaceuticals, a clinical stage pharmaceutical company and as Chief Financial and Operating Officer for First Place, AZ, a non-profit healthcare services organization. Mr. Cooper’s leadership experience is in clinical research, product development, supply chain, business development and executive management in a broad range of therapeutic areas including dermatology, aesthetics, allergy, sleep apnea, stroke and orphan drugs. Mr. Cooper currently serves as a director of Sonoran Biosciences, a specialty pharmaceutical company. He has also served as a director of Bioenvision (Nasdaq: BIVN). Mr. Cooper holds an MBA from the WP Carey School of Business at Arizona State University and a BA from Northeastern Illinois University.

Mr. Sember has served as a director of Quoin Inc. since May 2021 and as a director of Quoin Ltd. since October 28, 2021. In his 40-year career, Mr. Sember has been COO or CEO of five diverse pharmaceutical companies ranging from drug discovery tool providers, to therapeutically-focused biotechnology companies, to medical devices. He served as Chief Executive Officer of RaeSedo, Inc., of Regulonix Holding, and of Palyon Medical Corporation. At Marion Laboratories (later Marion Merrell Dow) Mr. Sember handled roles including sales, research and R&D program management. As Executive VP of Business Development for Élan Corporation, he was responsible for strategic collaborations, mergers and acquisitions. Mr. Sember has consulted for numerous companies and has extensive public and private board experience. He has served as the Chairman of the Board of Paylon Medical Corporation and of BioIndustry Organization of Southern Arizona, a non-profit trade group. Currently Mr. Sember serves as Chair of the Screening Panel and Board member for the number-one-ranked Desert Angels, a Tucson, AZ-based group of angel investors. Mr. Sember earned a Bachelor of Science degree from the University of Pittsburgh and an MBA from Rockhurst University.

Dr. Myers has more than 30 years of industry experience in the drug delivery and specialty pharmaceutical sectors. He previously served as CEO of Innocoll, Inc. and was responsible for taking that company public in 2014. He has also served as president of the drug delivery division of West Pharmaceutical Services, president of pharmaceutical operations for Fuisz Technologies (Biovail) and has held executive positions in Flamel Technologies and Elan Corporation. Dr. Myers earned his Ph.D. in Chemistry from the University College Cork. Dr. Myers has served as a director of Ethicann Pharmaceuticals and SquareX Pharmaceuticals, each a clinical stage pharmaceutical company. Since 2019, Dr. Myers has served as a director of Sonoran Bioscience and Wellesley Pharmaceuticals, each a specialty pharmaceutical company

Ms. Carter has over 30 years of experience in the drug delivery and specialty pharmaceutical industries. Prior to Quoin, Ms. Carter held various positions with Innocoll, Inc., including president Innocoll Pharmaceuticals and executive vice president of business development and corporate affairs of Innocoll Inc. She also served as vice president of business development of the drug delivery division of West Pharmaceuticals, and she has held executive positions at Eurand and Fuisz Technologies (Biovail). Ms. Carter earned her MBA from Wharton School of Business, University of Pennsylvania and a B.S. in Chemistry from the College of William and Mary.

Mr. Dunn joined Quoin Pharmaceuticals in November of 2021. He brings over 30 years of finance experience and has served as CFO of both private and publicly traded companies. In addition, Mr. Dunn has deep experience in investment banking and private equity. Over the last five years he has served as Chief Financial Officer for several private companies, most recently with Qured, a UK-based healthcare provider, from 2020 to 2021. Mr. Dunn also served as CFO of Innocoll Inc. from 2012-2016. Prior to joining Innocoll, Mr. Dunn had 20 years’ experience in investment banking and private equity, including over ten years managing the private equity funds of NewSmith Capital, and nine years at Merrill Lynch where he served as co-head of the European Private Equity Group and Director of Equity Capital Markets. Mr. Dunn received a B.A. from Stanford University and a J.D. from New York University School of Law.